HIK — Hikma Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapNeutral

Annual income statement for Hikma Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	C2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,203	2,341	2,553	2,517	2,875
Cost of Revenue
Gross Profit	1,095	1,213	1,301	1,265	1,407
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,669	1,739	1,955	2,208	2,513
Operating Profit	534	602	598	309	362
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	491	558	544	233	281
Provision for Income Taxes
Net Income After Taxes	487	430	420	191	192
Minority Interest
Net Income Before Extraordinary Items
Net Income	486	431	421	188	190
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	486	431	421	188	190
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.16	1.5	1.66	2.03	2.21
Dividends per Share